Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
暂无分享,去创建一个
S. Croft | A. Voak | K. Seifert | Iñigo Angulo-Barturen | Santiago Ferrer-Bazaga | A. Harris | Jose Miguel Coteron-Lopez
[1] J. Berman. Liposomal Amphotericin B Treatment and the Leishmaniases , 2019, The American journal of tropical medicine and hygiene.
[2] J. Adler-Moore,et al. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Juan A. Bueren-Calabuig,et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition , 2019, Proceedings of the National Academy of Sciences.
[4] S. Croft. Leishmania and other intracellular pathogens: selectivity, drug distribution and PK–PD , 2017, Parasitology.
[5] E. Khalil,et al. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study , 2017, The Journal of antimicrobial chemotherapy.
[6] J. Schellens,et al. Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs , 2017, Clinical Pharmacokinetics.
[7] S. Croft,et al. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis , 2017, Antimicrobial Agents and Chemotherapy.
[8] Ian H. Gilbert,et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need , 2017, Nature Reviews Microbiology.
[9] N. Stone,et al. Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions , 2016, Drugs.
[10] A. Descoteaux,et al. Leishmania survival in the macrophage: where the ends justify the means. , 2015, Current opinion in microbiology.
[11] T. Gumbo,et al. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. , 2015, The Journal of infectious diseases.
[12] S. Croft,et al. Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine , 2015, Gene Therapy.
[13] D. Andes,et al. Antifungal pharmacokinetics and pharmacodynamics. , 2015, Cold Spring Harbor perspectives in medicine.
[14] D. Caridha,et al. Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis , 2014, PLoS neglected tropical diseases.
[15] J. Beijnen,et al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. , 2014, The Journal of infectious diseases.
[16] Tove Tuntland,et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..
[17] P. Troke,et al. Tissue Penetration of Antifungal Agents , 2014, Clinical Microbiology Reviews.
[18] Peter G. Smith,et al. Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial , 2014, PLoS neglected tropical diseases.
[19] H. Derendorf,et al. Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents , 2013, Clinical Microbiology Reviews.
[20] J. Beijnen,et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. , 2012, The Journal of antimicrobial chemotherapy.
[21] J. Cano,et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.
[22] S. Stäger,et al. Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani , 2011, Journal of tropical medicine.
[23] O. Cars,et al. Protein Binding: Do We Ever Learn? , 2011, Antimicrobial Agents and Chemotherapy.
[24] K. Seifert. Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development , 2011, The open medicinal chemistry journal.
[25] Shyam Sundar,et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.
[26] S. Croft,et al. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. , 2010, The Journal of antimicrobial chemotherapy.
[27] Nigel J Waters,et al. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. , 2008, Journal of pharmaceutical sciences.
[28] G. Davies,et al. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. , 2008, Tuberculosis.
[29] O. Cars,et al. Tissue concentrations: do we ever learn? , 2007, The Journal of antimicrobial chemotherapy.
[30] R. Peeling,et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.
[31] G. Drusano. Pharmacokinetics and pharmacodynamics of antimicrobials. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Alan Forrest,et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] C. Wiedermann,et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. , 2006, The Journal of antimicrobial chemotherapy.
[34] S. Croft,et al. In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs , 2006, Antimicrobial Agents and Chemotherapy.
[35] P. Kaye,et al. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. , 2004, Trends in parasitology.
[36] H. Derendorf,et al. Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue , 2004, Antimicrobial Agents and Chemotherapy.
[37] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[38] T. Walsh,et al. Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate , 2002, Antimicrobial Agents and Chemotherapy.
[39] W. Craig,et al. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] D. Bradley,et al. Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. , 1977, Clinical and experimental immunology.